Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T96788
|
||||
Former ID |
TTDR01361
|
||||
Target Name |
mRNA of HER2
|
||||
Gene Name |
ERBB2
|
||||
Synonyms |
CD340 (mRNA); MLN 19 (mRNA); Metastatic lymph node gene 19 protein (mRNA); Proto-oncogene Neu (mRNA); Proto-oncogene c-ErbB-2 (mRNA); Tyrosine kinase-type cell surface receptor HER2 (mRNA); p185erbB2 (mRNA); ERBB2
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Breast cancer [ICD9: 174, 175; ICD10: C50] | ||||
Chronic pain [ICD9: 338.2,780; ICD10: R52.1-R52.2, G89] | |||||
Cancer [ICD9: 140-229; ICD10: C00-C96] | |||||
Function |
In the nucleus is involved in transcriptional regulation. Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Implicated in transcriptional activation of CDKN1A; the function involves STAT3 and SRC. Involvedin the transcription of rRNA genes by RNA Pol I and enhances protein synthesis and cell growth.
|
||||
BioChemical Class |
Kinase
|
||||
Target Validation |
T96788
|
||||
UniProt ID | |||||
EC Number |
EC 2.7.10.1
|
||||
Sequence |
MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNL
ELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNG DPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLA LTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQC AAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACP YNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSAN IQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLP DLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTV PWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQEC VEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARC PSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVG ILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETEL RKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSP YVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVR LVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFT HQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWM IDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDA EEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEG AGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYV NQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQ GGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV |
||||
Structure |
1MFG; 1MFL; 1MW4; 1N8Z; 1OVC; 1QR1; 1S78; 2A91; 2JWA; 2KS1; 2L4K; 3BE1; 3H3B; 3MZW; 3N85; 3PP0; 3RCD; 4GFU; 4HRL; 4HRM; 4HRN
|
||||
Drugs and Mode of Action | |||||
Inhibitor | (1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine | Drug Info | [526072] | ||
17-allylamino-17-desmethoxy-geldanamycin | Drug Info | [529815] | |||
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione | Drug Info | [528032] | |||
3,4-diphenyl-1H-pyrrole-2,5-dione | Drug Info | [528032] | |||
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione | Drug Info | [528032] | |||
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione | Drug Info | [528032] | |||
4-(3-phenoxylphenyl)-5-cyano-2H-1,2,3-triazole | Drug Info | [528580] | |||
4-(4-bromophenyl)-5-cyano-2H-1,2,3-triazole | Drug Info | [528580] | |||
4-(4-chlorophenyl)-5-cyano-2H-1,2,3-triazole | Drug Info | [528580] | |||
4-(4-isopropylphenyl)-5-cyano-2H-1,2,3-triazole | Drug Info | [528580] | |||
4-(Bis(2-chloroethyl)amino)-N-p-tolylbenzamide | Drug Info | [530574] | |||
4557W | Drug Info | [526072] | |||
AG-213 | Drug Info | [529134] | |||
BMS-536924 | Drug Info | [527711] | |||
BMS-690514 | Drug Info | [530732] | |||
CL-387785 | Drug Info | [528037] | |||
compound 38 | Drug Info | [532836] | |||
Geldanamycin-estradiol hybrid | Drug Info | [525501] | |||
HDS-029 | Drug Info | [528037] | |||
HKI-272 | Drug Info | [529214] | |||
N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide | Drug Info | [525502] | |||
PD-168393 | Drug Info | [525502] | |||
PNT-500 | Drug Info | [543538] | |||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | ErbB signaling pathway | ||||
Calcium signaling pathway | |||||
HIF-1 signaling pathway | |||||
Focal adhesion | |||||
Adherens junction | |||||
Pathways in cancer | |||||
Proteoglycans in cancer | |||||
MicroRNAs in cancer | |||||
Pancreatic cancer | |||||
Endometrial cancer | |||||
Prostate cancer | |||||
Bladder cancer | |||||
Non-small cell lung cancer | |||||
Central carbon metabolism in cancer | |||||
NetPath Pathway | TCR Signaling Pathway | ||||
PANTHER Pathway | Cadherin signaling pathway | ||||
EGF receptor signaling pathway | |||||
Pathway Interaction Database | ErbB4 signaling events | ||||
ErbB2/ErbB3 signaling events | |||||
ErbB receptor signaling network | |||||
a6b1 and a6b4 Integrin signaling | |||||
Validated targets of C-MYC transcriptional repression | |||||
PathWhiz Pathway | Phosphatidylinositol Phosphate Metabolism | ||||
Reactome | SHC1 events in ERBB2 signaling | ||||
PLCG1 events in ERBB2 signaling | |||||
PIP3 activates AKT signaling | |||||
GRB2 events in ERBB2 signaling | |||||
PI3K events in ERBB2 signaling | |||||
Constitutive Signaling by Aberrant PI3K in Cancer | |||||
Sema4D induced cell migration and growth-cone collapse | |||||
RAF/MAP kinase cascade | |||||
WikiPathways | DNA Damage Response (only ATM dependent) | ||||
ErbB Signaling Pathway | |||||
EGF/EGFR Signaling Pathway | |||||
Extracellular vesicle-mediated signaling in recipient cells | |||||
Bladder Cancer | |||||
Signaling by ERBB2 | |||||
Integrated Pancreatic Cancer Pathway | |||||
Signaling Pathways in Glioblastoma | |||||
Leptin signaling pathway | |||||
miR-targeted genes in muscle cell - TarBase | |||||
Semaphorin interactions | |||||
References | |||||
Ref 525501 | Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8.Synthesis and evaluation of geldanamycin-estradiol hybrids. | ||||
Ref 525502 | J Med Chem. 1999 May 20;42(10):1803-15.Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding siteof the epidermal growth factor receptor. | ||||
Ref 526072 | Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5.Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. | ||||
Ref 527711 | J Med Chem. 2005 Sep 8;48(18):5639-43.Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. | ||||
Ref 528032 | J Med Chem. 2006 Feb 23;49(4):1271-81.Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. | ||||
Ref 528037 | J Med Chem. 2006 Feb 23;49(4):1475-85.Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors. | ||||
Ref 528580 | Bioorg Med Chem. 2007 Feb 1;15(3):1533-8. Epub 2006 Dec 15.Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase. | ||||
Ref 529134 | Eur J Med Chem. 2008 Jul;43(7):1478-88. Epub 2007 Sep 29.Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors. | ||||
Ref 529214 | Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41. Epub 2007 Dec 6.Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. | ||||
Ref 529815 | Bioorg Med Chem. 2009 Mar 15;17(6):2225-35. Epub 2008 Nov 6.Discovery and development of heat shock protein 90 inhibitors. | ||||
Ref 530574 | Bioorg Med Chem. 2010 Jan 15;18(2):880-6. Epub 2009 Nov 22.Synthesis, biological evaluation and molecular docking studies of amide-coupled benzoic nitrogen mustard derivatives as potential antitumoragents. | ||||
Ref 530732 | Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93. | ||||
Ref 532836 | Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.